| Patient | John Locke |
|---|---|
| Date of birth | 1632-09-08 |
| Identifiers | MRN HR-EN001-SYN-TD; SSN (made up) 000-01-8305 |
| Document date | 1692-10-22 |
| Author | Prudence Hartwell-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Asthma review two weeks after a cold with a yellow-zone flare. [S]
Mr. Locke returns two weeks after his sick visit for a cold that triggered a yellow-zone flare. He took up to 11 inhalations of budesonide-formoterol on the worst day and never needed prednisolone. His peak flow climbed back above 400 L/min by the fifth day and has been 420 to 440 since. The cold cleared in about a week, and he stopped acetaminophen after four days. The review planned for one week after the sick visit did not take place: the clinic's first slot was today. He now needs his reliever about once a week, sleeps through the night, and has no side effects from tiotropium (no dry mouth, difficulty passing urine, or eye pain). The open fires remain out of use. He would like his first zoster vaccine today. [S]
| Element | Detail |
|---|---|
| Flare | Yellow zone with a cold; managed by the action plan without prednisolone |
| Peak flow | Back to 420 to 440 L/min; 430 in clinic today |
| Reliever use | About once a week |
| Tiotropium | Four months; no side effects |
| Asthma Control Test | 21 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy back to normal |
| Respiratory | Negative | No cough, wheeze, or night waking now; breathless only on steep hills |
| Genitourinary | Negative | No difficulty passing urine |
| Eyes | Negative | No eye pain or blurred vision |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometry | Two puffs every 4 hours as needed | Respiratory tract route | 1692-03-12 to 1692-03-26 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | Two inhalations twice daily plus one as needed; no more than 12 a day | Respiratory tract route | 1692-03-26 | active | S |
| Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5) | Two inhalations once a day | Respiratory tract route | 1692-06-18 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for aches or fever, no more than 3 g a day | One or two tablets every 6 hours as needed; no more than six tablets a day | Oral route | 1692-10-08 to 1692-10-22 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1692-10-22 | Body height | 178 | cm | S |
| 1692-10-22 | Body weight | 62.8 | kg | S |
| 1692-10-22 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 1692-10-22 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1692-10-22 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1692-10-22 | Heart rate | 74 | /min | S |
| 1692-10-22 | Respiratory rate | 16 | /min | S |
| 1692-10-22 | Body temperature | 36.5 | Cel | S |
| 1692-10-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1692-10-22 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 430 | L/min | 80 percent of his personal best of 440 L/min | Normal | S |
| 1692-10-22 | Total score [ACT] | 21 | {score} | S |
Vital signs recorded on 1692-10-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Respiratory | Clear on quiet and forced breathing; oxygen saturation 97 percent |
| Mouth | No candidiasis |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluation | resolved | confirmed | R05.3 | S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit. |
| Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at home | active | confirmed | Z77.110 | S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted. |
| Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPD | active | confirmed | J45.40 | S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R). |
| Acute viral upper respiratory infection (common cold) with a yellow-zone asthma flare: peak flow 68 percent of personal best, managed with extra as-needed budesonide-formoterol by his action plan, without oral corticosteroids; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented autumn chest troubles (CLM-0014). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 21: well controlled |
| Imaging | Peak expiratory flow | At each visit after a flare, and at home with symptoms | Completed today | 430 L/min in clinic, 98 percent of his best |
| Survey | Review within one week after a flare | Within one week of any exacerbation | Deferred | Missed: the one-week review planned at the sick visit was not booked because no slot was free, and no telephone check was arranged. No harm resulted: his diary shows the peak flow back above 400 L/min by the fifth day without prednisolone. Corrective action: the clinic now books a review within one week, by telephone if no slot is free, whenever he calls or is seen for a flare, and this is written into his care plan |
| Survey | Review 1 to 3 months after a controller change, with an Asthma Control Test | 1 to 3 months after starting or changing controller treatment | Deferred | Partly missed: the twelve-week plan set the full review with an Asthma Control Test at four months, beyond the protocol's 1 to 3 months. The preventive visit at 13 weeks reviewed his symptoms, reliever use, and side effects, but no Asthma Control Test was recorded until today. No harm: he was well controlled at that visit and today. Corrective action: an Asthma Control Test is recorded at any visit where asthma is reviewed |
| Examination | Inhaler technique with his own devices | Every visit | Completed today | Both inhalers used correctly |
| Medication safety | Adherence and reliever use | Every visit | Completed today | No missed doses since the flare; reliever about once a week |
| Medication safety | Tiotropium side effects (dry mouth, urinary retention, angle-closure glaucoma symptoms) | After starting and at each visit | Completed today | None |
| Survey | Exacerbation history | Every visit | Completed today | One yellow-zone flare with a cold; no oral corticosteroids, emergency visits, or admissions |
| Self-management | Trigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergens | Every visit | Completed today | Open fires out of use; HEPA air cleaners running; air quality index checked before city trips; no new exposures |
| Self-management | Smoking and vaping status | Every visit | Completed today | Never smoker; no vaping; no secondhand smoke |
| Self-management | Written asthma action plan | Every visit and after every flare | Completed today | Reviewed after the flare; he used it correctly; unchanged |
| Medication safety | Step-up and step-down assessment | Every visit | Completed today | Well controlled at step 5 (add-on tiotropium); no step-down so soon after a flare; reconsider after three months of good control |
| Imaging | Spirometry | Every 1 to 2 years once stable | Up to date | Last done four months ago; next within a year |
| Imaging | FeNO | To monitor inhaled-corticosteroid response when needed | Not indicated | Low on treatment four months ago; control is good |
| Examination | Comorbidity surveillance | At diagnosis and at least yearly | Up to date | Screened at diagnosis; PHQ-2 0 at the preventive visit |
| Self-management | Vaccination status | Yearly | Completed today | Influenza, COVID-19, and RSV vaccines given five weeks ago; zoster dose 1 today |
| Medication safety | Biologic candidacy | When asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and technique | Not indicated | No exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Air Cleaners and Air Filters in the Home (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Asthma review in three months; zoster dose 2 in two to six months; spirometry within a year of the last. [S]